These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38582620)

  • 1. Comments on "GLP-1 agonists: A review for emergency clinicians".
    Mattingly TJ; LaFleur G; Ruble JH
    Am J Emerg Med; 2024 Jun; 80():194-196. PubMed ID: 38582620
    [No Abstract]   [Full Text] [Related]  

  • 2. New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists.
    George C; Byun A; Howard-Thompson A
    Am J Med; 2018 Nov; 131(11):1304-1306. PubMed ID: 29969616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
    Gupta A; Jelinek HF; Al-Aubaidy H
    Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin and glucagon-like peptide receptor agonist (GLP 1 RA) combinations.
    Kalra S
    J Pak Med Assoc; 2014 Mar; 64(3):359-61. PubMed ID: 24864619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current issues in GLP-1 receptor agonist therapy for type 2 diabetes.
    Bloomgarden ZT; Blonde L; Garber AJ; Wysham CH
    Endocr Pract; 2012; 18 Suppl 3():6-26; quiz 27-8. PubMed ID: 23315305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.
    Freeman JS
    J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S2-6. PubMed ID: 22267300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review.
    Yammine L; Kosten TR; Pimenova M; Schmitz JM
    Diabetes Res Clin Pract; 2019 Mar; 149():78-88. PubMed ID: 30735771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes.
    Edwards CM
    Br J Hosp Med (Lond); 2013 Apr; 74(4):198-201. PubMed ID: 23571389
    [No Abstract]   [Full Text] [Related]  

  • 10. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M
    Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 receptor agonists for type 2 diabetes.
    De Block CE; Van Gaal LF
    Lancet; 2009 Jul; 374(9683):4-6. PubMed ID: 19515414
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.
    Gargiulo P; Savarese G; D'Amore C; De Martino F; Lund LH; Marsico F; Dellegrottaglie S; Marciano C; Trimarco B; Perrone-Filardi P
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1081-1088. PubMed ID: 29113708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [GLP-1 agonists: an overview].
    Hinneburg I
    Med Monatsschr Pharm; 2013 Jul; 36(7):246-51. PubMed ID: 23898602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery Device Patents on GLP-1 Receptor Agonists.
    Alhiary R; Gabriele S; Kesselheim AS; Tu SS; Feldman WB
    JAMA; 2024 Mar; 331(9):794-796. PubMed ID: 38315473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diabetes therapy--novel drugs to come (DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors)].
    Gallwitz B
    MMW Fortschr Med; 2010 May; 152(20):43-4. PubMed ID: 20552881
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cardioprotective effects of glucagon-like peptide 1 receptor agonists].
    Ametov AS; Kamynina LL; Akhmedova ZG
    Kardiologiia; 2014; 54(7):92-6. PubMed ID: 25177820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal insulin or longacting GLP-1 receptor agonists-making the right choice.
    Bloomgarden ZT
    Lancet Diabetes Endocrinol; 2014 Jun; 2(6):439-41. PubMed ID: 24731676
    [No Abstract]   [Full Text] [Related]  

  • 19. Implications of GLP-1 agonist use on airway management.
    Mizubuti GB; Ho AM; da Silva LM
    Am J Emerg Med; 2024 Aug; 82():190-191. PubMed ID: 38821845
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.
    Garber AJ
    Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S279-84. PubMed ID: 21525469
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.